

Overview

Useful For

Determining the specific apolipoprotein E (*APOE*) genotypes in patients with type III hyperlipoproteinemia

APOE genotyping has been used to assess susceptibility for Alzheimer disease. However, the use of *APOE* analysis for predictive testing for Alzheimer disease **is not currently recommended** by the American College of Medical Genetics due to limited clinical utility and poor predictive value.

Special Instructions

- [Informed Consent for Genetic Testing](#)
- [Molecular Genetics: Neurology Patient Information](#)
- [Informed Consent for Genetic Testing \(Spanish\)](#)

Method Name

Polymerase Chain Reaction (PCR) including Restriction Digest

NY State Available

Yes

Specimen

Specimen Type

Varies

Shipping Instructions

Specimen preferred to arrive within 96 hours of collection.

Specimen Required

Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

Specimen Type: Whole blood

Container/Tube:

Preferred: Lavender top (EDTA) or yellow top (ACD)

Acceptable: Any anticoagulant

Specimen Volume: 3 mL

Collection Instructions:

1. Invert whole blood several times to mix blood. **Do not aliquot.**
2. Send specimen in original tube.

Forms

1. **New York Clients-Informed consent is required.** Document on the request form or electronic order that a copy is on file.

[-Informed Consent for Genetic Testing \(T576\)](#)

[-Informed Consent for Genetic Testing-Spanish \(T826\)](#)

2. [Molecular Genetics: Neurology Patient Information](#)

3. If not ordering electronically, complete, print, and send a [Neurology Specialty Testing Client Test Request \(T732\)](#) with the specimen.

Specimen Minimum Volume

1 mL

Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Varies	Ambient (preferred)		
	Frozen		
	Refrigerated		

Clinical & Interpretive

Clinical Information

Apolipoproteins are structural constituents of lipoprotein particles that participate in lipoprotein synthesis, secretion, processing, and metabolism. Apolipoproteins have critical roles in blood lipid metabolism. Defects in apolipoprotein E (ApoE) are responsible for familial dysbetalipoproteinemia, or type III hyperlipoproteinemia, in which increased plasma cholesterol and triglycerides result from impaired clearance of chylomicron and very-low-density lipoprotein remnants.

The human *APOE* gene is located on chromosome 19. The 3 common *APOE* alleles are designated e2, e3, and e4, which encode the ApoE isoforms E2, E3, and E4, respectively. E3, the most common isoform in the White population, shows cysteine (Cys) at amino acid position 112 and arginine (Arg) at position 158. E2 and E4 differ from E3 by single amino acid substitutions at positions 158 and 112, respectively (E2: Arg158->Cys; E4: Cys112->Arg). The allele frequencies for most White populations are as follows:

-e2=8% to 12%

-e3=74% to 78%

-e4=14% to 15%

E2 and E4 are both associated with higher plasma triglyceride concentrations. Over 90% of individuals with type III hyperlipoproteinemia are homozygous for the e2 allele. However, less than 10% of individuals homozygous for the e2 allele have overt type III hyperlipoproteinemia. This suggests that other genetic, hormonal, or environmental factors must contribute to the phenotypic expression of the disease. The e4 allele has been linked to pure elevations of low-density lipoproteins. Patients with a lipid profile consistent with type III hyperlipidemia are candidates for analysis of their *APOE* genotype.

The *APOE* gene is also a known susceptibility gene for Alzheimer disease. The e4 allele is associated with an increased risk for Alzheimer disease, particularly late-onset disease, in a dose-dependent manner. This risk is also influenced by other factors. It is estimated that individuals with the *APOE* e3/e4 genotype have a 4-fold relative risk for Alzheimer disease, while homozygotes for e4 allele have a 12-fold relative risk. Several studies have suggested a protective effect of the *APOE* e2 allele.

The *APOE* e4 allele, however, is neither sufficient nor necessary for the development of Alzheimer disease.

Approximately 50% of individuals with Alzheimer disease carry an e4 allele, and many individuals who have an e4 allele will never develop Alzheimer disease. The use of *APOE* analysis for predictive testing for Alzheimer disease is not currently recommended by the American College of Medical Genetics and Genomics due to limited clinical utility and poor predictive value.

Interpretation

An interpretive report will be provided.

Cautions

This assay will not detect all of the genetic variants that cause type III hyperlipoproteinemia. Therefore, the absence of a detectable genetic variant does not rule out the possibility that an individual is a carrier of or affected with this disease.

This assay cannot predict or rule out the development of Alzheimer disease in an individual.

Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. Errors in the interpretation of results may occur if information given is inaccurate or incomplete.

Rare variants (ie, polymorphisms) exist that could lead to false-negative or false-positive results. If results obtained do not match the clinical findings, additional testing should be considered.

In rare cases, DNA alterations of undetermined significance may be identified.

This assay does not identify all of the less common apolipoprotein E alleles. Thus, an individual who appears to be homozygous for e2, e3, or e4 may carry one of the rare alleles that cannot be detected by this assay.

Clinical Reference

1. Smelt AH, de Beer F: Apolipoprotein E and familial dysbetalipoproteinemia: Clinical, biochemical, and genetic aspects. *Semin Vasc Med.* 2004 Aug;4(3):249-257
2. Utermann G: Morgagni lecture: genetic polymorphism of apolipoprotein E-impact on plasma lipoprotein metabolism In: Crepaldi G, Tiengo A, Baggio G. *Diabetes, Obesity and Hyperlipidemias 3: Proceedings of the 4th European Symposium on Metabolism* 1985. Elsevier; 1985:1-28
3. Elosua R, Ordovas JM, Cupples LA, et al: Association of APOE genotype with carotid atherosclerosis in men and women: the Framingham Heart Study. *J Lipid Res.* 2004 Oct;45(10):1868-1875
4. Poirier J, Davignon J, Bouthillier D, et al: Apolipoprotein E polymorphism and Alzheimer's disease. *Lancet.* 1993 Sep;342(8873): 697-699
5. Farrer L, Cupples A, Haines J, et al: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. *JAMA.* 1997 Oct 22-29;278(16):1349-1356
6. Goldman JS, Hahn SE, Catania JW, et al: Genetic counseling and testing for Alzheimer disease: joint practice guidelines

of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med. 2011 Jun;13(6):597-605

7. American College of Medical Genetics and Genomics: Five things physicians and patients should question. Choosing Wisely; 2015. Updated July 1, 2021. Accessed October 27, 2021. Available at www.choosingwisely.org/societies/american-college-of-medical-genetics-and-genomics/

Performance

Method Description

A polymerase chain reaction-based assay, which includes HhaI digestion of the amplified product, is utilized to identify the 3 most common apolipoprotein E alleles (e2, e3, e4).(Unpublished Mayo method)

PDF Report

No

Day(s) Performed

Wednesday

Report Available

9 to 10 days

Performing Laboratory Location

Rochester

Fees & Codes

Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

Test Classification

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

81401-APOE (apolipoprotein E) (eg, hyperlipoproteinemia type III, cardiovascular disease, Alzheimer disease), common variants (eg, *2, *3, *4)

LOINC® Information

Test ID	Test Order Name	Order LOINC® Value
---------	-----------------	--------------------

APOEG	Apolipoprotein E Genotyping, B	42315-2
-------	--------------------------------	---------

Result ID	Test Result Name	Result LOINC® Value
53198	Result Summary	50397-9
53199	Result	42315-2
53200	Interpretation	69047-9
53201	Reason for Referral	42349-1
53202	Specimen	31208-2
53203	Source	31208-2
53204	Released By	18771-6